Citadel Advisors - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 117 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$14,237,668
+17.2%
2,010,970
+16.6%
0.00%0.0%
Q2 2023$12,143,725
-8.2%
1,724,961
+8.7%
0.00%0.0%
Q1 2023$13,231,994
+21.8%
1,586,570
+67.6%
0.00%0.0%
Q4 2022$10,866,038
-52.0%
946,519
-47.3%
0.00%
-50.0%
Q3 2022$22,630,000
+76.0%
1,796,015
+47.7%
0.01%
+100.0%
Q2 2022$12,861,000
-40.9%
1,215,661
-9.1%
0.00%
-40.0%
Q1 2022$21,747,000
-4.3%
1,337,456
-18.5%
0.01%
+25.0%
Q4 2021$22,721,000
-38.4%
1,640,473
-36.1%
0.00%
-50.0%
Q3 2021$36,889,000
+5.8%
2,567,054
+16.4%
0.01%0.0%
Q2 2021$34,872,000
+78.6%
2,205,703
+14.9%
0.01%
+60.0%
Q1 2021$19,520,000
-62.9%
1,919,412
-72.8%
0.01%
-64.3%
Q4 2020$52,644,000
+68.4%
7,066,317
-22.4%
0.01%
+75.0%
Q3 2020$31,261,000
-26.6%
9,100,731
+1.9%
0.01%
-42.9%
Q2 2020$42,565,000
+241.9%
8,932,808
+43.5%
0.01%
+180.0%
Q1 2020$12,451,000
-39.6%
6,225,434
+4.1%
0.01%
-44.4%
Q4 2019$20,630,000
+87.3%
5,979,879
+55.5%
0.01%
+80.0%
Q3 2019$11,017,000
-19.3%
3,845,171
+6.8%
0.01%
-16.7%
Q2 2019$13,651,000
-25.2%
3,601,898
+60.7%
0.01%
-33.3%
Q1 2019$18,239,000
+213.8%
2,240,775
+211.1%
0.01%
+200.0%
Q4 2018$5,812,000
+1300.5%
720,204
+1226.7%
0.00%
Q3 2018$415,000
+8.6%
54,287
-18.6%
0.00%
Q2 2018$382,000
-82.7%
66,689
-85.6%
0.00%
-100.0%
Q1 2018$2,204,000
+1204.1%
462,079
+1235.5%
0.00%
Q4 2017$169,000
-97.8%
34,600
-97.6%
0.00%
-100.0%
Q3 2017$7,585,000
+664.6%
1,447,547
+711.1%
0.01%
+500.0%
Q2 2017$992,000
-35.4%
178,458
-2.4%
0.00%0.0%
Q1 2017$1,536,000
+57.4%
182,825
+18.5%
0.00%0.0%
Q4 2016$976,000
+308.4%
154,254
+185.1%
0.00%
Q3 2016$239,000
-85.4%
54,100
-62.4%
0.00%
-100.0%
Q3 2015$1,641,000
-86.2%
143,954
-81.9%
0.00%
-80.0%
Q2 2015$11,863,000
+3409.8%
794,591
+2025.5%
0.01%
Q1 2015$338,000
-63.0%
37,384
-60.0%
0.00%
-100.0%
Q3 2014$914,000
-25.3%
93,409
-2.8%
0.00%0.0%
Q2 2014$1,224,000
+973.7%
96,068
+787.8%
0.00%
Q1 2014$114,000
-64.9%
10,821
-74.7%
0.00%
Q4 2013$325,000
+606.5%
42,803
+42.8%
0.00%
Q2 2013$46,00029,9740.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q4 2017
NameSharesValueWeighting ↓
Burrage Capital Management LLC 1,105,673$8,237,0006.28%
Sarissa Capital Management LP 8,175,000$60,903,0006.22%
ORACLE INVESTMENT MANAGEMENT INC 2,980,870$22,207,0002.78%
DG Capital Management, LLC 1,075,732$8,014,0001.70%
Ghost Tree Capital, LLC 900,000$6,705,0001.49%
Parkman Healthcare Partners LLC 538,370$4,011,0001.03%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 5,835,810$43,477,0000.86%
Formidable Asset Management, LLC 470,419$3,470,0000.80%
KNOTT DAVID M 219,461$1,635,0000.74%
Altium Capital Management LP 250,000$1,863,0000.70%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders